| Datasets | Category | Treg source | Type | TotalDEGs | CS up | /DEGs% | CS down | /DEGs% |
|---|---|---|---|---|---|---|---|---|
| GSE116347 | Lymphoid | Tumor bearing mouse (B16) spleen | RNA-seq | 1218 | 125 | 10.26 | 49 | 4.02 |
| GSE116347 | Lymphoid | Tumor bearing mouse (MC38) spleen | RNA-seq | 1298 | 147 | 11.33 | 69 | 5.32 |
| GSE116347 | Lymphoid | Tumor bearing mouse (CT26) spleen | RNA-seq | 905 | 103 | 11.38 | 38 | 4.20 |
| GSE120280 | Lymphoid | Tumor bearing mouse (TC-1) spleen | RNA-seq | 1776 | 194 | 10.92 | 96 | 5.41 |
| GSE139372 | Non-lymphoid | Melanoma Skin | RNA-seq | 1571 | 71 | 4.52 | 158 | 10.06 |
| GSE120280 | Non-lymphoid | Tumor bearing mouse (TC-1) tumor | RNA-seq | 1933 | 161 | 8.33 | 97 | 5.02 |
| GSE89225 | Non-lymphoid | Breast Tumor | RNA-seq | 1493 | 83 | 5.56 | 122 | 8.17 |
| GSE116347 | Non-lymphoid | Tumor bearing mouse (B16) tumor | RNA-seq | 2462 | 173 | 7.03 | 138 | 5.61 |
| GSE116347 | Non-lymphoid | Tumor bearing mouse (MC38) tumor | RNA-seq | 1651 | 143 | 8.66 | 90 | 5.45 |
| GSE116347 | Non-lymphoid | Tumor bearing mouse (CT26) tumor | RNA-seq | 1393 | 61 | 4.38 | 182 | 13.07 |
CS, canonical secretome; DEG, differentially expressed gene.
IPA analysis was performed to identify commonly shared upregulated canonical secretome pathways in malignant disease spleen Treg and tumor tissue Treg. A total of 17 activated canonical secretome pathways were enriched in malignant Treg groups. The most commonly shared pathways were p38 MAPK Signaling and IL-6 Signaling. Specifically enriched pathways in malignant spleen Treg and tumor tissue Treg were as following: HMGB1 Signaling and Cardiac Hypertrophy Signaling (Enhanced) were enriched in GSE116347 B16 spleen Treg. Type I Diabetes Mellitus Signaling was enriched in GSE116347 MC38 spleen Treg. GP6 Signaling Pathway and CDK5 Signaling were enriched in GSE120280 TC-1 spleen Treg. Pancreatic Adenocarcinoma Signaling, ILK Signaling and Antiproliferative Role of TOB in T Cell Signaling were enriched in GSE116347 MC38 tumor Treg. SPINK1 Pancreatic Cancer Pathway, PTEN Signaling, and Inhibition of Matrix Metalloproteases were enriched in GSE116347 CT26 tumor Treg. LPS/IL-1 Mediated Inhibition of RXR Function was enriched in GSE139372 melanoma Treg. Osteoarthritis Pathway was enriched in GSE89255 breast cancer Treg. (cut off: p < 0.05 and |Z-score| >= 2)